<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Tracheo- and broncho-esophageal fistulas in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Tracheo- and broncho-esophageal fistulas in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Tracheo- and broncho-esophageal fistulas in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adnan Majid, MD, FCCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fayez Kheir, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Henri G Colt, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 18, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2102910844">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathological connections between the esophagus and the trachea or major bronchi are termed tracheoesophageal fistula (TEF) and bronchoesophageal fistula (BEF), respectively. Although uncommon, they can be a major source of significant morbidity and mortality, particularly in patients with esophageal or lung cancer. Since the etiologies and management are similar for TEF and BEF, for the purposes of this topic, both will be referred to as TEF.
        </p>
        <p>
         This topic will discuss the clinical features, diagnosis, and treatment of patients with TEF and BEF. Bronchopleural and alveolopleural fistulas are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/115897.html" rel="external">
          "Bronchopleural fistula in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116036.html" rel="external">
          "Alveolopleural fistula and prolonged air leak in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2967226698">
         <span class="h1">
          ETIOLOGIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most TEFs in adults are acquired and due to esophageal or lung cancer. Congenital TEFs are rare in adults.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acquired – Malignancy, typically esophageal or lung cancer, accounts for over 50 percent of TEFs. However, TEFs are rare as a complication of malignancy; about 5 to 15 percent of patients with esophageal malignancy and 1 percent of patients with bronchogenic carcinoma develop TEF [
         <a href="#rid1">
          1-4
         </a>
         ]. Less commonly, TEFs are due to benign conditions (eg, prolonged endotracheal intubation, surgical or endoscopic interventions, mediastinal granuloma)  (
         <a class="graphic graphic_table graphicRef117661" href="/z/d/graphic/117661.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital – Most congenital TEFs present in childhood and are typically associated with esophageal atresia. Rarely, a small congenital H-type TEF (communicates with a normal esophagus) may present in adulthood [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6377.html" rel="external">
          "Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H248700749">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         TEF should be suspected in patients with a known risk factor who have one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Frequent coughing following solid and liquid intake
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent purulent bronchitis or pneumonia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent aspiration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained malnutrition
        </p>
        <p>
        </p>
        <p>
         Patients who are receiving mechanical ventilation can develop TEF from prolonged endotracheal intubation and may present with acute respiratory distress, worsening oxygenation, loss of tidal volume during ventilation, and gastric distension.
        </p>
        <p>
         In most patients, the symptoms develop over days to weeks (eg, those due to malignancy) while in others the symptoms may be acute (over hours; eg, those due to intubation). The onset may also depend upon the location and size of the fistula in that large proximal TEFs may present earlier than smaller distal TEFs.
        </p>
        <p>
         Symptoms of the underlying cause may also be present (eg, cough and hemoptysis from lung cancer or dysphagia and weight loss from esophageal cancer).
        </p>
        <p>
         Since the condition is uncommon and the symptoms are nonspecific, the diagnosis is often delayed.
        </p>
        <p class="headingAnchor" id="H2367706478">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         An esophagram and endoscopy should be performed in patients with suspected TEF. There are no specific laboratory findings, although some patients with lung infection may have a leukocytosis or elevated erythrocyte sedimentation rate. TEFs should be identified and treated promptly since spontaneous closure is rare and if left untreated, patients progress to respiratory failure and death. There are no guidelines on how best to evaluate and diagnose TEFs. Our approach, outlined in this section, is based upon observational series and our experience.
        </p>
        <p class="headingAnchor" id="H1712305567">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of TEF is traditionally made with contrast-enhanced esophagography that demonstrates displacement of the contrast into the lung;
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         preparation is preferred over Gastrografin because the latter is extremely hypertonic and can induce pulmonary edema, pneumonia, or death, whereas aspiration of small amounts of barium seems to have little clinical relevance [
         <a href="#rid6">
          6
         </a>
         ]. In patients who cannot swallow (eg, mechanically ventilated patients), contrast studies may not be feasible such that chest computed tomography (CT) is an alternative. Chest CT scan with three-dimensional reconstruction and oral or intravenous contrast medium may localize the fistula, identify details of the fistula etiology, and examine tracheal/esophageal anatomy, all of which are important for evaluating potential therapies.
        </p>
        <p class="headingAnchor" id="H4186386732">
         <span class="h2">
          Endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases, bronchoscopy and/or endoscopy should be performed to confirm imaging findings and localize the fistula  (
         <a class="graphic graphic_picture graphicRef117663" href="/z/d/graphic/117663.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef117651" href="/z/d/graphic/117651.html" rel="external">
          picture 2
         </a>
         ). In cases where a malignant etiology is suspected a biopsy should be performed to confirm the diagnosis. However, recognition of smaller fistulas can be challenging especially if the mucosa is red and swollen. Orally administered
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         before bronchoscopy with observation of bubbles leaking into the airway has been described as helpful in identifying small fistulas [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4280892195">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of TEF is usually based upon a combination of clinical, radiographic, and endoscopic findings. While contrast imaging, computed tomography, and endoscopy are not always necessary for the diagnosis, all three are typically done since they provide complementary diagnostic and therapeutic information.
        </p>
        <p class="headingAnchor" id="H2485568030">
         <span class="h1">
          MANAGEMENT AND OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spontaneous closure of TEF is rare. Without treatment, the outcome is poor and can be measured in weeks. The management of TEF requires a multidisciplinary approach involving thoracic surgery, oncology, gastroenterology, and interventional pulmonary experts. Careful assessment of the etiology, size, anatomy (tracheal and esophageal), burden of the underlying disease, and patient comorbidities as well as the risk-benefit ratio of various repair options should be undertaken when deciding about the best treatment approach. In general, surgery with a curative intent is usually performed for benign TEF [
         <a href="#rid8">
          8
         </a>
         ], whereas palliative management is reserved for malignant TEF  (
         <a class="graphic graphic_algorithm graphicRef117794" href="/z/d/graphic/117794.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117793" href="/z/d/graphic/117793.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_table graphicRef117661" href="/z/d/graphic/117661.html" rel="external">
          table 1
         </a>
         ). Since malignancy is the more common etiology, palliative endoscopic/bronchoscopic treatments are more frequently administered.
        </p>
        <p>
         There is a paucity of data and no consensus or guidelines on how best to manage TEF. Significant variation among clinicians exists but practice is evolving as expertise in interventional pulmonology grows. The approach outlined here is influenced by our expertise in interventional pulmonology and we recognize that this strategy may not always be universally applied, particularly when interventional expertise is not available.
        </p>
        <p class="headingAnchor" id="H2201342773">
         <span class="h2">
          Initial general measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial general measures that should be undertaken include eliminating oral intake, keeping the head of the bed elevated at 45 degrees or greater, administering anti-reflux therapy, frequent oral suctioning, treating pulmonary infection/aspiration pneumonia, and oxygenation with supplemental oxygenation (if indicated). Nasogastric tubes should be removed, if present. A gastrostomy tube is also sometimes placed to suction gastric contents which potentially reduces further leak from gastroesophageal reflux (eg, mechanically ventilated patient or patient with TEF in the lower one-third of the esophagus). In patients who are considered for endoscopic stenting some experts recommend placing a gastrostomy or jejunostomy tube prophylactically for enteral nutrition. If this is not feasible, total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         is appropriate.
        </p>
        <p>
         If patients are receiving mechanical ventilation, extubation is preferable but is not always feasible. For those who cannot be extubated, bypassing the site of the TEF by advancing the endotracheal tube (ETT) or placing an extra-long tracheostomy tube, should be performed ensuring that the inflated cuff is below the fistula; ETTs or tracheostomy tubes with continuous subglottic aspiration (if available) are preferable. Some experts also lower the tidal volume and positive end-expiratory pressure in an attempt to minimize air leak through the fistula and avoid TEF enlargement, although this maneuver is of unproven benefit. Many experts wait until patients are weaned off mechanical ventilation before attempting surgical repair since it has been shown that positive pressure ventilation is associated with an increased incidence of anastomotic dehiscence and restenosis following surgery [
         <a href="#rid1">
          1,9-13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2071930258">
         <span class="h2">
          Treat underlying cause
         </span>
         <span class="headingEndMark">
          —
         </span>
         While therapy is mostly aimed at treating the fistulous communication, efforts targeted at treating the underlying cause should be simultaneously undertaken  (
         <a class="graphic graphic_table graphicRef117661" href="/z/d/graphic/117661.html" rel="external">
          table 1
         </a>
         ). This may involve treating any underlying disorder such as malignancy or infection, or removing the patient from mechanical ventilation, if feasible.
        </p>
        <p class="headingAnchor" id="H1199668539">
         <span class="h2">
          Malignant lesions (palliative therapy)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with malignant TEF are treated palliatively  (
         <a class="graphic graphic_algorithm graphicRef117794" href="/z/d/graphic/117794.html" rel="external">
          algorithm 1
         </a>
         ). While there are rare case reports of malignant TEF being treated surgically (eg, surgically fit patients with minimally invasive localized disease or surgery after oncologic therapy), it is not generally recommended and frequently not feasible [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Patients or lesions suitable for surgery'
         </a>
         below.)
        </p>
        <p>
         The treatment for most malignant TEFs, particularly those &gt;5 mm involves stenting of the esophagus, airway, or both. A smaller proportion of patients have small lesions (eg, ≤5 mm) which are generally treated with local bronchoscopic therapies (eg, clipping or fibrin glue). The choice of palliative intervention depends upon lesion size and location as well as level of expertise and patient comorbidities. In most cases, a complete or partial response can be achieved to allow patients to survive a few more weeks or months with an improved quality of life. The rationale for this approach is based upon our experience and that of others [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2228955532">
         <span class="h3">
          Fistula in mid-proximal esophagus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of TEFs are located in the middle one-third of the esophagus (since most cancers are located within this region), and most of those are treated with double stenting (ie, sequential placement of tracheal and esophageal stents).
        </p>
        <p class="headingAnchor" id="H3325752254">
         <span class="h4">
          First line: Double (combined) stenting
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with malignant TEF involving the mid to proximal esophagus, airway (typically tracheal) stenting in addition to esophageal stenting should be performed. While an airway stent is indicated in those with an associated stenotic airway lesion, it is also appropriate in those without airway stenosis. Unlike distal esophageal stents, stents placed in the mid to proximal portion of the esophagus can result in potential airway obstruction once the esophageal stent is fully expanded; thus, placement of an airway stent prior to the esophageal stent can prevent this complication [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         One retrospective study evaluated the clinical efficacy of airway stenting in 61 patients with TEF [
         <a href="#rid17">
          17
         </a>
         ]. Almost every patient who underwent double stenting had a complete response (defined as no leakage of contrast medium after radiography and clinical symptom resolution without recurrence for more than two weeks) compared with two-thirds of patients who had airway stenting alone. In another retrospective study of 30 patients with large fistulas and airway stenosis, patients who received a double stent had a greater mean survival than those who received an airway stent alone (110 versus 24 days) [
         <a href="#rid18">
          18
         </a>
         ]. In another study of 112 patients with TEF, double stenting was associated with improved survival when compared with airway stenting alone (252 versus 219 days) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H165602824">
         <span class="h5">
          Airway stent
         </span>
         <span class="headingEndMark">
          —
         </span>
         The airway stent should be placed first followed by the esophageal stent, preferably in one setting, although one procedure is not always feasible; this reduces the risk of airway obstruction by the esophageal stent and decreases the risk of esophageal stent migration.
        </p>
        <p>
         Airway stents should cover at least 20 mm beyond the proximal and distal margin of the fistula  (
         <a class="graphic graphic_picture graphicRef117659" href="/z/d/graphic/117659.html" rel="external">
          picture 3
         </a>
         ). In addition, the stent should be 10 to 20 percent larger than the internal airway diameter at the fistula site. Straight stents are often used for proximal airway TEFs while L- or Y-shaped ones are used for lower airway TEFs.
        </p>
        <p>
         Factors that affect success include apposition between the stent and esophageal and/or tracheal wall around the fistula, adequacy of stent covering of the fistula, and the degree of associated esophageal or tracheal stenosis. A variety of airway stents are available for clinical application in the tracheobronchial tree for treatment of TEF. Options include covered self-expanding metal stents (ie, tubular mesh that is partially or fully covered), silicone stents, or hybrid stents. Although there are no comparative studies available, we prefer to use covered self-expanding metal stents since they have the following advantages over silicone stents:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preferable inner diameter to wall thickness ratio.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excellent expansion and adherence to the tracheal wall creating a good seal (silicone stents do not self-expand so they do not conform to the tracheal wall as readily).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fewer episodes of stent migration (due to the above); although fully covered metallic stents may migrate more than partially covered, both migrate less than silicone stents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less airway obstruction due to improved secretion clearance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ease of insertion using a flexible bronchoscope (silicone stents require a rigid bronchoscope).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Available sizes for larger airways (airway diameter &gt;18 mm and ≤20 mm; silicone stents not available for large airways)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ease of deployment, which decreases the risk of expanding the size of the TEF orifice at the time of stent placement.
        </p>
        <p>
        </p>
        <p>
         The disadvantages of using a metallic over a silicone stent are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater tumor in growth and esophageal spill (of food particles and liquid material) into the trachea through partially covered metal stent interstices (at the proximal and distal end of the stent, which is not covered).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Difficulty removing (often due to tumor infiltration and excellent adherence properties of the partially covered stents).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less durability due to increased risk of stent fracture (500 to 1000 days).
        </p>
        <p>
        </p>
        <p>
         Thus, a fully covered metallic stent may be preferred for patients with malignant fistulas [
         <a href="#rid20">
          20,21
         </a>
         ], those in whom short-term use is planned, for TEF associated with tortuous airways, those with an airway diameter &gt;18 and ≤20 mm, or TEF located in upper and mid airway (stents placed in the upper airway have a greater chance of migrating than those in the lower airway). On the other hand, a silicone stent may be preferred when long-term use is needed (eg, &gt;500 days or when TEF is associated with benign airway stenosis) since they last longer and are more durable than metallic stents.
        </p>
        <p>
         Details regarding the insertion, complications, and follow-up of airway stents are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4403.html" rel="external">
          "Airway stents", section on 'Insertion technique'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4403.html" rel="external">
          "Airway stents", section on 'Follow-up'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4403.html" rel="external">
          "Airway stents", section on 'Complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2816749542">
         <span class="h5">
          Esophageal stent
         </span>
         <span class="headingEndMark">
          —
         </span>
         The upper margin of the esophageal stent should be slightly higher than the upper margin of airway stent, which is thought to reduce the risk of esophageal stent migration  (
         <a class="graphic graphic_picture graphicRef117662" href="/z/d/graphic/117662.html" rel="external">
          picture 4
         </a>
         ). The stent length and diameter are chosen according to the location of the lesion, size of the TEF and degree of esophageal stenosis. Stents must cover 2 cm beyond the proximal and distal margins of the TEF, should be wide enough to press firmly against the esophageal wall, and are usually placed under direct visualization through endoscopy or under fluoroscopy. Technical details and efficacy of stenting for esophageal lesions are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/2677.html" rel="external">
          "Endoscopic stenting for palliation of malignant esophageal obstruction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H886373808">
         <span class="h4">
          Second line options
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second line options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airway stent alone – Airway stenting alone  (
         <a class="graphic graphic_picture graphicRef117659" href="/z/d/graphic/117659.html" rel="external">
          picture 3
         </a>
         ) (ie, without concomitant esophageal stent) is indicated in rare circumstances when an esophageal stent is not feasible. Examples include TEF located in the high proximal esophagus (where an esophageal stent is often not feasible since patients do not tolerate them due to pain), TEF associated with a completely occluded esophageal lumen that precludes the passage of an esophageal guide wire, and severe esophageal stenosis that is at risk of rupture from esophageal stenting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Esophageal stent – If an esophageal stent is feasible but an airway stent is not, due to the size of the airway (≥20 mm), then an esophageal stent may be placed, taking into consideration that airway encroachment and worsening of fistula size are potential complications. (See
         <a class="local">
          'Esophageal stent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H140308802">
         <span class="h3">
          Distal esophagus fistulas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Distal esophageal fistulas are less common than mid or proximal ones and are more likely to communicate with major bronchi than with the trachea (ie, BEF). Management is dependent upon whether or not endobronchial stenosis is present.
        </p>
        <p class="headingAnchor" id="H4124235851">
         <span class="h4">
          No airway stenosis: Esophageal stent
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with large TEFs/BEFs in the distal esophagus without concomitant airway stenosis, an esophageal stent  (
         <a class="graphic graphic_picture graphicRef117662" href="/z/d/graphic/117662.html" rel="external">
          picture 4
         </a>
         ) alone is indicated. An airway stent is not needed since esophageal stents in this location are not typically associated with airway compromise or worsening TEF [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="local">
          'First line: Double (combined) stenting'
         </a>
         above.)
        </p>
        <p>
         Few studies have selectively compared outcomes using individual stenting strategies. Nonetheless, one prospective study reported survival rates of 263 days in those with esophageal stents compared with 219 days for those who received an airway stent alone and 252 days for those who received a combined airway-esophageal stent [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         If an esophageal stent migrates (eg, because there is no esophageal stenosis), TEF is persistent or worsened by the stent, or the airway is compromised by the stent, esophageal stent replacement with a concomitant airway stent are options (ie, double stenting). (See
         <a class="local">
          'First line: Double (combined) stenting'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3301863518">
         <span class="h4">
          Airway stenosis: Double stent
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with large TEFs in the distal esophagus with concomitant airway stenosis (typically bronchial), double stenting is indicated. Bronchial stents are not more difficult or less feasible to place than tracheal stents. Bronchial stents can be placed up to distal left main stem bronchus and distal right bronchus intermedius. A frequent problem that is encountered with right BEF when the communication is at the level of the right upper lobe (RUL) bronchus is that in order to seal the defect, the RUL needs to be removed from ventilation (ie, "jailed") with a stent that is placed from the right main stem (RMS) bronchus and the bronchus intermedius (BI). Another problem with right-sided BEF is that there can be a size mismatch between the RMS and the BI so placing a stent of ideal size and fit can be an issue. In this case, a custom three-dimensional printed silicone stent can be considered, although experience with this novel approach is limited [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="local">
          'First line: Double (combined) stenting'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1689169090">
         <span class="h2">
          Benign lesions (potentially curative)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The intent of treating benign TEF is curative with surgery. However, not all patients or lesions are suitable for surgical repair. Importantly, definitive surgical repair cannot be performed unless the underlying disorder is curable and site of potential anastomosis is disease-free  (
         <a class="graphic graphic_algorithm graphicRef117793" href="/z/d/graphic/117793.html" rel="external">
          algorithm 2
         </a>
         ). Palliative procedures are frequently performed as a bridge to surgery while the underlying disorder is being treated.
        </p>
        <p class="headingAnchor" id="H1033075273">
         <span class="h3">
          Patients or lesions suitable for surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical repair is technically difficult surgery that uses a cervicotomy, cervicosternotomy, or thoracotomy approach; thus, expertise in both esophageal and tracheal surgery are critical for success. The surgical approach for TEF depends upon the size of the fistula [
         <a href="#rid1">
          1,23,24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For small lesions, the fistula is divided and repaired using one or two layers of omental or muscle flaps (between the esophagus and trachea) over a nasogastric tube.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large fistulas with tracheal injury may require major esophageal and/or tracheal surgery including any combination of the following: esophageal diversion (esophagostomy) or resection, full thickness skin graft esophageal reconstruction, tracheal or laryngotracheal resection and reconstruction, and muscle flap interposition.
        </p>
        <p>
        </p>
        <p>
         Immediate extubation following surgery is the goal since it is thought that postoperative mechanical ventilation may lead to wound dehiscence and fistula recurrence. (See
         <a class="local">
          'Initial general measures'
         </a>
         above.)
        </p>
        <p>
         Successful fistula closure following surgical intervention for benign TEF has been reported in 75 to 94 percent of patients with median follow-up times between 23 months and 12.5 years [
         <a href="#rid25">
          25-29
         </a>
         ]. The majority are able to resume oral intake (&gt;70 percent) and do not require prolonged mechanical ventilation after surgery. One retrospective study reported that in patients with benign TEF, reintervention was less likely in those who had surgery compared with patients who had non-surgical interventions (eg, stenting) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Surgery is frequently fraught with complications (up to 50 percent) [
         <a href="#rid23">
          23-25,27,30
         </a>
         ]. Perioperative mortality as high as 11 percent has been reported. Major complications include wound dehiscence, recurrent TEF, pneumonia, vocal cord paralysis, and tracheal stenosis.
        </p>
        <p class="headingAnchor" id="H1982730043">
         <span class="h3">
          Patients or lesions not suitable for surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with benign lesions who are
         <strong>
          not
         </strong>
         good surgical candidates (eg, critically ill patients) or who have lesions not suitable for surgery (eg, large fistulas that prohibit reconstruction or resection or fistulas that involve or are close to the major vessels [eg, following esophagectomy]) should undergo palliation or local therapy depending on size. Such interventions are also indicated in patients who need a bridge to surgery (eg, patients on mechanical ventilation or receiving antibiotics for infection).
        </p>
        <p class="headingAnchor" id="H3163110993">
         <span class="h4">
          Fistulas &gt;5 mm: Palliative interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients in this subgroup are treated with palliative stenting similar to those with malignant TEF. However, most experts deploy only one stent, airway or esophageal, rather than double stenting. The choice of stent depends upon which site can achieve the best "fit" (ie, better sealing effect) and local expertise. When one stent does not seal the defect, then double stenting is appropriate. This approach is based upon the rationale that, unlike malignant lesions, the ideal goal of stenting for benign lesions is to provide a bridge to curative surgery; this strategy maximizes the sealing effect with a single stent and minimizes the risk of stent-related complications. For example, double stenting may interfere with the healing process long term because of the constant friction and radial pressure between stent walls, and unlike malignant fistulas, benign fistulas have less risk of airway obstruction after deployment of an esophageal stent in the mid to proximal region, thereby decreasing the need for double stenting. The details of palliative interventions are discussed above. (See
         <a class="local">
          'Malignant lesions (palliative therapy)'
         </a>
         above.)
        </p>
        <p>
         In few selected patients, TEF healing might be achieved by a mini-invasive approach using an Amplatzer septal occluder, which is available in different sizes and intended for cardiac septal defect closure. It is composed of a nitinol mesh, has two self-expandable disks connected by a thin diameter waist, and ensures mechanical closure of the two sides of the fistula  (
         <a class="graphic graphic_diagnosticimage graphicRef141315" href="/z/d/graphic/141315.html" rel="external">
          image 1
         </a>
         ), making a potential platform for subsequent tissue ingrowth [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Three-dimensional designed metallic and silicone segmented Y airway stents have been used to construct personalized stents that are congruent to the airways [
         <a href="#rid32">
          32
         </a>
         ]. However, such technology is not widely available and requires considerable communication between the physician and the manufacturer and a significant level of experience from all parties involved.
        </p>
        <p class="headingAnchor" id="H2248227152">
         <span class="h4">
          Fistulas ≤5 mm: Local therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local therapies are usually preferred in patients with small benign lesions based upon the rationale that risks of stent insertion and their complications outweigh the benefits; stenting is reserved for those who fail local therapies.
        </p>
        <p class="headingAnchor" id="H3637887048">
         <span class="h5">
          Endoscopic clip placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal over-the-scope-clipping (OTSC) is a new generation technique that allows closure of gastrointestinal defects including fistulas. The OTSC device is attached to an applicator integrated onto the tip of the endoscope. It requires soft and expandable tissue in order to launch, and is therefore only applied to the gastrointestinal side of the TEF. The major benefits of such devices are speed (procedural time is on average measured in minutes), ease of deployment, and persistent sealing. Small case reports suggest adequate fistula closure following OTSC in TEF [
         <a href="#rid33">
          33-36
         </a>
         ], but further studies are needed to adequately assess outcome in this population with this technique.
        </p>
        <p class="headingAnchor" id="H4163863756">
         <span class="h5">
          Occlusive therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Closure of small TEFs with local injection of tissue adhesive, fibrin glue, vascular plugs, septal occluders, or silicon rings has been used in individual cases with variable success [
         <a href="#rid37">
          37-42
         </a>
         ]. However, such methods are uncommonly used owing to their temporary effect and dissolution of occlusive material two weeks following injection leading to recanalization of the fistula.
        </p>
        <p class="headingAnchor" id="H4129329265">
         <span class="h5">
          Investigational therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laser and argon plasma coagulation thermal ablation have also been used in children for refractory congenital TEF in an attempt to promote re-epithelialization [
         <a href="#rid43">
          43,44
         </a>
         ]. However, success has not been reported in adults with non-congenital TEF. (See
         <a class="medical medical_review" href="/z/d/html/2273.html" rel="external">
          "Endoscopic palliation of esophageal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3637278246">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most circumstances patients should undergo a repeat contrast-enhanced esophagram within 48 hours following therapy to make sure complete seal has been achieved and to prevent further pulmonary soiling. In addition, patients should be monitored for symptom relief and maintenance of the response. A complete response is one where no leak is identified and the patient can resume eating and drinking for a minimum of two weeks. A partial response is one where the leak is reduced and symptoms improve for the same time period; however, patients cannot eat. In the latter, reintervention may be considered depending upon the original procedure; this may involve stent replacement, placement of a concomitant airway stent (if not already in place), and/or additional local therapies. There should be a low threshold to re-image and perform endoscopy or bronchoscopy in those who develop new or progressive symptoms that suggest fistula recurrence (up to 11 percent in benign acquired TEF) or a stent-related complication (like obstruction), which is not unusual [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3243813600">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Tracheoesophageal fistula (TEF) is a pathological connection between the esophagus and trachea. Most TEFs in adults are acquired and due to esophageal or lung cancer  (
         <a class="graphic graphic_table graphicRef117661" href="/z/d/graphic/117661.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Etiologies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – TEF should be suspected in patients with a known risk factor who have coughing following solid and liquid intake, recurrent purulent bronchitis or pneumonia, and malnutrition. The diagnosis is usually based upon a combination of clinical, radiographic (esophagram and/or chest computed tomography), and endoscopic findings that demonstrate a leak or fistulous communication  (
         <a class="graphic graphic_picture graphicRef117663" href="/z/d/graphic/117663.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef117651" href="/z/d/graphic/117651.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial management
         </strong>
         – The management of TEF requires a multidisciplinary approach (thoracic surgery, oncology, gastroenterology, interventional pulmonary). Initial therapeutic measures include eliminating oral intake, keeping the head of the bed elevated ≥45 degrees, administering anti-reflux therapy, oral suctioning, treating pulmonary infection, oxygenation, and hyperalimentation. Efforts targeted at treating the underlying cause should simultaneously be undertaken. (See
         <a class="local">
          'Initial general measures'
         </a>
         above and
         <a class="local">
          'Treat underlying cause'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mid-proximal esophagus fistula
         </strong>
         – For patients with malignant TEF located in the mid to proximal esophagus, we suggest combined esophageal and airway stenting (double stenting) rather than an esophageal or airway stent alone  (
         <a class="graphic graphic_algorithm graphicRef117794" href="/z/d/graphic/117794.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); for those in whom an esophageal stent is not feasible, an airway stent alone is appropriate. Since spontaneous closure is rare and TEF leads to progressive deterioration, stenting is a palliative measure targeted at relieving symptoms or delaying death. (See
         <a class="local">
          'Fistula in mid-proximal esophagus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distal esophagus fistula
         </strong>
         – For patients with malignant TEF located in the distal esophagus who are without concomitant airway stenosis, we suggest an esophageal stent rather than a double stent  (
         <a class="graphic graphic_algorithm graphicRef117794" href="/z/d/graphic/117794.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); double stenting can be reserved for those with associated airway stenosis or those who fail esophageal stenting alone. (See
         <a class="local">
          'Distal esophagus fistulas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benign lesions
         </strong>
         – For patients with benign TEF, who are good surgical candidates and in whom surgery is technically feasible, we recommend surgical repair rather than nonsurgical treatments (eg, stenting)  (
         <a class="graphic graphic_algorithm graphicRef117793" href="/z/d/graphic/117793.html" rel="external">
          algorithm 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ) based upon the rationale that this therapy is curative. For patients with benign TEF &gt;5 mm in whom surgical repair is not feasible or patients who need a bridge to surgery, palliative measures (typically single stenting with esophageal or airway stent) are indicated. For patients with benign TEF &lt;5 mm who are not surgical candidates, local endoscopic therapies (eg, clipping, fibrin glue) are appropriate based upon the rationale that risks of stent insertion and their complications outweigh the benefit in this population; stenting is reserved for those who fail local therapies. (See
         <a class="local">
          'Benign lesions (potentially curative)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Following therapy, patients should undergo a repeat contrast-enhanced esophagram within 48 hours and clinical assessment for symptom response. There should be a low threshold to re-image and perform endoscopy in those who develop new or progressive symptoms that suggest fistula recurrence or a stent-related complication. For patients with benign TEF who undergo successful surgery, the outcome is typically good. For patients with malignant TEF who undergo palliative approaches, symptoms typically improve but recurrence from the underlying cause is common. (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Reed MF, Mathisen DJ. Tracheoesophageal fistula. Chest Surg Clin N Am 2003; 13:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YH, Li SH, Chiu YC, et al. Comparative study of esophageal stent and feeding gastrostomy/jejunostomy for tracheoesophageal fistula caused by esophageal squamous cell carcinoma. PLoS One 2012; 7:e42766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balazs A, Kupcsulik PK, Galambos Z. Esophagorespiratory fistulas of tumorous origin. Non-operative management of 264 cases in a 20-year period. Eur J Cardiothorac Surg 2008; 34:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez AN, Diaz-Jimenez JP. Malignant respiratory-digestive fistulas. Curr Opin Pulm Med 2010; 16:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drucker NA, Cox CS Jr. Adult presentation of congenital tracheooesophageal fistula treated as asthma and recurrent respiratory infections. Lancet 2023; 402:2326.
          </a>
         </li>
         <li class="breakAll">
          Gore RM, Levine M. Textbook of Gastrointestinal Radiology, 2nd ed, W. B. Saunders Company, Philadelphia, PA 2000.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathisen DJ, Grillo HC, Wain JC, Hilgenberg AD. Management of acquired nonmalignant tracheoesophageal fistula. Ann Thorac Surg 1991; 52:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bibas BJ, Cardoso PFG, Minamoto H, Pêgo-Fernandes PM. Surgery for intrathoracic tracheoesophageal and bronchoesophageal fistula. Ann Transl Med 2018; 6:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gudovsky LM, Koroleva NS, Biryukov YB, et al. Tracheoesophageal fistulas. Ann Thorac Surg 1993; 55:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartels HE, Stein HJ, Siewert JR. Tracheobronchial lesions following oesophagectomy: prevalence, predisposing factors and outcome. Br J Surg 1998; 85:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robins B, Das AK. Anesthetic management of acquired tracheoesophageal fistula: a brief report. Anesth Analg 2001; 93:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chauhan SS, Long JD. Management of Tracheoesophageal Fistulas in Adults. Curr Treat Options Gastroenterol 2004; 7:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah CP, Yeolekar ME, Pardiwala FK. Acquired tracheo-oesophageal fistula. J Postgrad Med 1994; 40:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenz CJ, Bick BL, Katzka D, et al. Esophagorespiratory Fistulas: Survival and Outcomes of Treatment. J Clin Gastroenterol 2018; 52:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou C, Hu Y, Xiao Y, Yin W. Current treatment of tracheoesophageal fistula. Ther Adv Respir Dis 2017; 11:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bick BL, Song LM, Buttar NS, et al. Stent-associated esophagorespiratory fistulas: incidence and risk factors. Gastrointest Endosc 2013; 77:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ke M, Wu X, Zeng J. The treatment strategy for tracheoesophageal fistula. J Thorac Dis 2015; 7:S389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freitag L, Tekolf E, Steveling H, et al. Management of malignant esophagotracheal fistulas with airway stenting and double stenting. Chest 1996; 110:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herth FJ, Peter S, Baty F, et al. Combined airway and oesophageal stenting in malignant airway-oesophageal fistulas: a prospective study. Eur Respir J 2010; 36:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holden VK, Ospina-Delgado D, Chee A, et al. Safety and Efficacy of the Tracheobronchial Bonastent: A Single-Center Case Series. Respiration 2020; 99:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avasarala SK, Sethi S, Machuzak M, et al. A Single-Center Case Series Describing Tracheobronchial Bonastent Implantation. J Bronchology Interv Pulmonol 2019; 26:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng GZ, Folch E, Wilson A, et al. 3D printing and personalized airway stents. Pulm Ther 2017; 3:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas AN. The diagnosis and treatment of tracheoesophageal fistula caused by cuffed tracheal tubes. J Thorac Cardiovasc Surg 1973; 65:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovesi T, Rubin S. Long-term complications of congenital esophageal atresia and/or tracheoesophageal fistula. Chest 2004; 126:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muniappan A, Wain JC, Wright CD, et al. Surgical treatment of nonmalignant tracheoesophageal fistula: a thirty-five year experience. Ann Thorac Surg 2013; 95:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baisi A, Bonavina L, Narne S, Peracchia A. Benign tracheoesophageal fistula: results of surgical therapy. Dis Esophagus 1999; 12:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camargo JJ, Machuca TN, Camargo SM, et al. Surgical treatment of benign tracheo-oesophageal fistulas with tracheal resection and oesophageal primary closure: is the muscle flap really necessary? Eur J Cardiothorac Surg 2010; 37:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macchiarini P, Verhoye JP, Chapelier A, et al. Evaluation and outcome of different surgical techniques for postintubation tracheoesophageal fistulas. J Thorac Cardiovasc Surg 2000; 119:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen KR, Allen MS, Cassivi SD, et al. Surgical management of acquired nonmalignant tracheoesophageal and bronchoesophageal fistulae. Ann Thorac Surg 2010; 90:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bibas BJ, Guerreiro Cardoso PF, Minamoto H, et al. Surgical Management of Benign Acquired Tracheoesophageal Fistulas: A Ten-Year Experience. Ann Thorac Surg 2016; 102:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siboni S, D'Aiello AF, Chessa M, Bonavina L. Tailored endoscopic treatment of tracheo-oesophageal fistula using preoperative holographic assessment and a cardiac septal occluder. BMJ Case Rep 2022; 15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang W, Shan Q, Wu Z, et al. Retrievable covered metallic segmented Y airway stent for gastrorespiratory fistula of carina or main bronchi. J Thorac Cardiovasc Surg 2021; 161:1664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traina M, Curcio G, Tarantino I, et al. New endoscopic over-the-scope clip system for closure of a chronic tracheoesophageal fistula. Endoscopy 2010; 42 Suppl 2:E54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinnamala S, Murthy B, Parmar J, et al. Rendezvous technique using bronchoscopy and gastroscopy to close a tracheoesophageal fistula by placement of an over-the-scope clip. Endoscopy 2014; 46 Suppl 1 UCTN:E301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armellini E, Crinò SF, Orsello M, et al. Novel endoscopic over-the-scope clip system. World J Gastroenterol 2015; 21:13587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           So BJ, Adler DG. Closure of a Chronic, Non-Healing Tracheoesophageal Fistula With a New Over-the-Scope Clip. ACG Case Rep J 2014; 2:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scappaticci E, Ardissone F, Baldi S, et al. Closure of an iatrogenic tracheo-esophageal fistula with bronchoscopic gluing in a mechanically ventilated adult patient. Ann Thorac Surg 2004; 77:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cellier C, Landi B, Faye A, et al. Upper gastrointestinal tract fistulae: endoscopic obliteration with fibrin sealant. Gastrointest Endosc 1996; 44:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Gao X, Chen J, et al. Endoscopic closure of acquired oesophagorespiratory fistulas with cardiac septal defect occluders or vascular plugs. Respir Med 2015; 109:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erdim I, Sirin AA, Baykal B, et al. Treatment of large persistent tracheoesophageal peristomal fistulas using silicon rings. Braz J Otorhinolaryngol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitz S, Van Damme JP, Hamoir M. A simple technique for closure of persistent tracheoesophageal fistula after total laryngectomy. Otolaryngol Head Neck Surg 2009; 140:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumonceau JM, Cremer M, Lalmand B, Devière J. Esophageal fistula sealing: choice of stent, practical management, and cost. Gastrointest Endosc 1999; 49:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rakoczy G, Brown B, Barman D, et al. KTP laser: an important tool in refractory recurrent tracheo-esophageal fistula in children. Int J Pediatr Otorhinolaryngol 2010; 74:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatnagar V, Lal R, Sriniwas M, et al. Endoscopic treatment of tracheoesophageal fistula using electrocautery and the Nd:YAG laser. J Pediatr Surg 1999; 34:464.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 115157 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12755313" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Tracheoesophageal fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22912737" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Comparative study of esophageal stent and feeding gastrostomy/jejunostomy for tracheoesophageal fistula caused by esophageal squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18678504" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Esophagorespiratory fistulas of tumorous origin. Non-operative management of 264 cases in a 20-year period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20531081" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Malignant respiratory-digestive fistulas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38103939" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Adult presentation of congenital tracheooesophageal fistula treated as asthma and recurrent respiratory infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38103939" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Adult presentation of congenital tracheooesophageal fistula treated as asthma and recurrent respiratory infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1929626" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Management of acquired nonmalignant tracheoesophageal fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30023373" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Surgery for intrathoracic tracheoesophageal and bronchoesophageal fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8466341" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Tracheoesophageal fistulas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9529504" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Tracheobronchial lesions following oesophagectomy: prevalence, predisposing factors and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11574354" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Anesthetic management of acquired tracheoesophageal fistula: a brief report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14723836" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Management of Tracheoesophageal Fistulas in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8737559" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acquired tracheo-oesophageal fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27824640" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Esophagorespiratory Fistulas: Survival and Outcomes of Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28391759" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Current treatment of tracheoesophageal fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23245798" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Stent-associated esophagorespiratory fistulas: incidence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26807286" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The treatment strategy for tracheoesophageal fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8915213" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Management of malignant esophagotracheal fistulas with airway stenting and double stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20525708" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Combined airway and oesophageal stenting in malignant airway-oesophageal fistulas: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32259817" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Safety and Efficacy of the Tracheobronchial Bonastent: A Single-Center Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30829896" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A Single-Center Case Series Describing Tracheobronchial Bonastent Implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : 3D printing and personalized airway stents
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4697451" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The diagnosis and treatment of tracheoesophageal fistula caused by cuffed tracheal tubes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364774" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Long-term complications of congenital esophageal atresia and/or tracheoesophageal fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23000263" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Surgical treatment of nonmalignant tracheoesophageal fistula: a thirty-five year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10631915" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Benign tracheoesophageal fistula: results of surgical therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19800809" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Surgical treatment of benign tracheo-oesophageal fistulas with tracheal resection and oesophageal primary closure: is the muscle flap really necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10649202" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Evaluation and outcome of different surgical techniques for postintubation tracheoesophageal fistulas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20732517" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Surgical management of acquired nonmalignant tracheoesophageal and bronchoesophageal fistulae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27329192" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Surgical Management of Benign Acquired Tracheoesophageal Fistulas: A Ten-Year Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35272993" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Tailored endoscopic treatment of tracheo-oesophageal fistula using preoperative holographic assessment and a cardiac septal occluder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32340805" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Retrievable covered metallic segmented Y airway stent for gastrorespiratory fistula of carina or main bronchi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20157889" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : New endoscopic over-the-scope clip system for closure of a chronic tracheoesophageal fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25058822" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Rendezvous technique using bronchoscopy and gastroscopy to close a tracheoesophageal fistula by placement of an over-the-scope clip.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26730172" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Novel endoscopic over-the-scope clip system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26157894" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Closure of a Chronic, Non-Healing Tracheoesophageal Fistula With a New Over-the-Scope Clip.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726094" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Closure of an iatrogenic tracheo-esophageal fistula with bronchoscopic gluing in a mechanically ventilated adult patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8979068" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Upper gastrointestinal tract fistulae: endoscopic obliteration with fibrin sealant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25980770" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Endoscopic closure of acquired oesophagorespiratory fistulas with cardiac septal defect occluders or vascular plugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27472983" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Treatment of large persistent tracheoesophageal peristomal fistulas using silicon rings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19328355" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A simple technique for closure of persistent tracheoesophageal fistula after total laryngectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9869726" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Esophageal fistula sealing: choice of stent, practical management, and cost.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20060599" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : KTP laser: an important tool in refractory recurrent tracheo-esophageal fistula in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10211655" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Endoscopic treatment of tracheoesophageal fistula using electrocautery and the Nd:YAG laser.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
